Celltrion’s Humira Biosimilar Receives U.S. FDA Interchangeability Designation for all Its Approved Dosages and Strengths May 23, 2025
Expert Reaction: U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
U.S. FDA Gives Its Nod to Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD